Journal of the Japan Diabetes Society
Online ISSN : 1881-588X
Print ISSN : 0021-437X
ISSN-L : 0021-437X
Search
Advanced search
OR
Browse
Search
Current issue
Displaying 1-7 of 7 articles from this issue
Show all abstracts
    • |<
    • <
    • 1
    • >
    • >|
Feature
Digital Medicine in Diabetes Care: Current and Future Directions
Case Report
  • A Woman With Type 2 Diabetes Mellitus and Lung Adenocarcinoma Who Developed Diabetic Ketoacidosis after Concomitant Use of Anamorelin and SGLT2 Inhibitor: A Case Report
    Fumiya Sato, Junko Sato, Nozomu Yamasaki, Yukiko Sugawara, Takashi Fun ...
    2024 Volume 67 Issue 6 Pages 252-256
    Published: June 30, 2024
    Released on J-STAGE: June 30, 2024
    DOIhttps://doi.org/10.11213/tonyobyo.67.252
    JOURNAL RESTRICTED ACCESS
    Show abstractHide abstract

    A 68-year-old woman diagnosed with lung adenocarcinoma and brain metastases underwent chemotherapy. She also had type 2 diabetes for approximately eight years, but her HbA1c level was controlled at approximately 7 % without drug therapy. Later, when dexamethasone was added to her chemotherapy regimen, her glycemic control deteriorated, and sitagliptin was started. She also developed cancer cachexia and began treatment with anamorelin hydrochloride, which has ghrelin effects. Thirteen days later, ipragliflozin was started because of elevated blood glucose levels, and four days later, the patient was urgently admitted due to diabetic ketoacidosis (DKA). After hospitalization, the patient discontinued oral medication, and DKA improved with insulin therapy. In this case, the combination of anamorelin hydrochloride and sodium glucose cotransporter (SGLT) 2 inhibitors during chemotherapy with dexamethasone was considered to be the cause of DKA. It is necessary to warn that a combination of these drugs in the terminal stage of cancer may lead to the development of DKA.

    View full abstract
    Download PDF (387K)
Letters to the Editor
    • |<
    • <
    • 1
    • >
    • >|
feedback
 Top